ArticleCancer medicine2025
Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based Studies.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
purposeAccurate classification of prostate cancer (PC) disease states defined by the presence or absence of metastasis and castration resistance (CRPC) is critical but challenging in population-based research. As chart review is not feasible on a large scale, accurate automated methods are needed.
methodsWe conducted a retrospective study using data from the Veterans Affairs Health Care System to evaluate algorithms for identifying CRPC and metastatic PC, with manual chart review as the gold standard. Our analysis included 8336 patients for CRPC classification and 721 for metastatic disease classification. For CRPC classification, we assessed one novel algorithm using criteria including rising prostate-specific antigen levels or progression to metastatic disease while receiving androgen deprivation therapy or initiating CRPC-specific treatments. For metastatic disease detection, we assessed four algorithms based on: ICD codes alone, natural language processing (NLP) alone, a novel algorithm combining ICD codes and treatment patterns, and an enhanced version of the novel algorithm integrating NLP, evaluating the sensitivity and specificity of each. Positive and negative predictive values were reported across a range of assumed disease prevalence.
resultsOut of 8336 patients with PC, 1190 (14.3%) were identified as having CRPC through chart review, with the CRPC algorithm achieving 85.1% sensitivity and 96.1% specificity. Among 721 patients evaluated for metastatic disease, 179 (24.8%) were identified as having metastatic disease through chart review. The algorithm combining ICD codes, treatment patterns, and NLP demonstrated the highest sensitivity (94.4%) and high specificity (93.0%), while other methods had lower sensitivity with varied specificity.
conclusionsOur findings suggest that our CRPC algorithm and the combined ICD codes, treatment patterns, and NLP algorithm for metastasis are effective automated approaches for identifying advanced states of PC. In particular, integrating NLP boosted sensitivity for metastatic classification with minimal specificity trade-off, highlighting the value of a multifaceted approach to large-scale PC research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.